Twist in hepatocellular carcinoma: pathophysiology and therapeutics

被引:14
|
作者
Zou, Hui [1 ]
Feng, Xing [1 ]
Cao, Jian-Guo [1 ]
机构
[1] Hunan Normal Univ, Coll Med, Changsha 410013, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; Epithelial to mesenchymal transition; Metastasis; Twist; Cancer stem cells; CANCER STEM-CELLS; EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; E-CADHERIN; EXPRESSION; ACTIVATION; METASTASIS; GENE; PROLIFERATION;
D O I
10.1007/s12072-015-9634-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related disease worldwide. Although HCC is mainly associated with viral hepatitis and alcoholic cirrhosis, numerous physiological and biochemical events are associated with HCC progression. The transcription factor Twist, which plays a key role in epithelial to mesenchymal transition, is reported to be associated with HCC. Overexpression of Twist causes various biochemical changes, such as increase of cell proliferation, reduction of apoptosis, cell cycle deregulation, generation of hepatic cancer stem cells, and in some cases, drug resistance. These changes result in various physiological changes, such as angiogenesis, cellular migration and invasion, and vasculogenic mimicry, which ultimately causes hepatocellular metastasis. Interestingly, targeting Twist via different strategies, especially small RNA technology, has shown promising therapeutic potential for future HCC treatment.
引用
收藏
页码:399 / 405
页数:7
相关论文
共 50 条
  • [1] Twist in hepatocellular carcinoma: pathophysiology and therapeutics
    Hui Zou
    Xing Feng
    Jian-Guo Cao
    Hepatology International, 2015, 9 : 399 - 405
  • [2] Interplay of Extracellular Vesicles and TLR4 Signaling in Hepatocellular Carcinoma Pathophysiology and Therapeutics
    Papadakos, Stavros P.
    Arvanitakis, Konstantinos
    Stergiou, Ioanna E.
    Vallilas, Christos
    Sougioultzis, Stavros
    Germanidis, Georgios
    Theocharis, Stamatios
    PHARMACEUTICS, 2023, 15 (10)
  • [3] Recent therapeutics in hepatocellular carcinoma
    Fan, Zhe
    Zhou, Pengcheng
    Jin, Binghui
    Li, Guangyao
    Feng, Lu
    Zhuang, Chengjun
    Wang, Shuang
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (01): : 261 - 275
  • [4] Improved therapeutics for hepatocellular carcinoma
    Zavadil, Jessica A.
    Walter, Christi A.
    CANCER RESEARCH, 2016, 76
  • [5] Development of MicroRNA Therapeutics for Hepatocellular Carcinoma
    Aravalli, Rajagopal N.
    DIAGNOSTICS, 2013, 3 (01): : 170 - 191
  • [6] RNA Interference as Therapeutics for Hepatocellular Carcinoma
    Xu, Chuanrui
    Lee, Susie A.
    Chen, Xin
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2011, 6 (01) : 106 - 115
  • [7] The Effect of Twist Expression on Angiogenesis in Hepatocellular Carcinoma
    Gangmin Xi1 Lin Zhang1 Zhongli Zhan2 Lihua Zhang2 Xiyin Wei1 Yi Yang1 Yurong Shi1 Fei Zhang1 Ruifang Niu1 1 Central Laboratory of Oncology
    Chinese Journal of Clinical Oncology, 2006, (06) : 413 - 418
  • [8] Development and novel therapeutics in hepatocellular carcinoma: a review
    Ingle, Pravinkumar Vishwanath
    Samsudin, Sarah Zakiah
    Chan, Pei Qi
    Ng, Mei Kei
    Heng, Li Xuan
    Yap, Siu Ching
    Chai, Amy Siaw Hui
    Wong, Audrey San Ying
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 445 - 455
  • [9] Current discovery strategies for hepatocellular carcinoma therapeutics
    Dai, Qiuzi
    Zhang, Cunlong
    Yuan, Zigao
    Sun, Qinsheng
    Jiang, Yuyang
    EXPERT OPINION ON DRUG DISCOVERY, 2020, 15 (02) : 243 - 258
  • [10] Current concepts in pathophysiology and management of hepatocellular carcinoma
    Hamza, Amal H.
    Abdulfattah, Hanaa M.
    Mahmoud, Rasha H.
    Khalil, Wagdy K. B.
    Ahmed, Hanaa H.
    ACTA BIOCHIMICA POLONICA, 2015, 62 (03) : 573 - 580